GSK plc filed a Form 6-K with the U.S. Securities and Exchange Commission on 20 November 2026, disclosing the transfer of 22,000,000 ordinary treasury shares to JPMorgan Chase Bank, N.A. to procure the issuance of 11,000,000 ADRs for employee incentive plan awards.
Key Highlights
- Shares transferred: 22,000,000 ordinary shares of 31¼ pence each were moved from treasury to JPMorgan Chase Bank, N.A., the depositary of the company's ADR programme.
- ADRs issued: 11,000,000 ADRs of the company were procured for transfer to the GlaxoSmithKline (US) Trust.
- Consideration received: $47.82 per ADR, representing $23.91 per ordinary share, funded by a contribution from GlaxoSmithKline LLC.
- Purpose: ADRs are to be used to satisfy awards granted under the Deferred Annual Bonus Plan, Performance Share Plan, and Share Value Plan.
- Treasury shares remaining: Following the transfer, the company will hold 248,881,064 ordinary shares in treasury.
- Shares in issue: 4,067,451,066 ordinary shares are in issue, excluding treasury shares, which also represents the total number of voting rights.
- Treasury share voting rights percentage: Following the transfer, treasury shares represent 6.12% of voting rights, as confirmed in accordance with DTR 5.5.1R.
GSK Deploys Treasury Shares to Fund Employee Award Programmes
According to the filing, on 20 November 2026, GSK plc transferred 22,000,000 ordinary shares of 31¼ pence each that were held in treasury to JPMorgan Chase Bank, N.A., the depositary of the company's American depositary receipts programme. The transfer was made to procure the issuance and transfer of 11,000,000 ADRs to the GlaxoSmithKline (US) Trust. The company disclosed that these ADRs are intended to satisfy awards granted under its Deferred Annual Bonus Plan, Performance Share Plan, and Share Value Plan.
The filing states that the consideration received from the trustee of the Trust was $47.82 per ADR, equating to $23.91 per ordinary share. This consideration was funded by a contribution to the Trust from GlaxoSmithKline LLC. The announcement was made in accordance with UK Listing Rule 9.8.2, the filing noted.
Following the transaction, the company disclosed it will hold 248,881,064 ordinary shares in treasury, with 4,067,451,066 ordinary shares in issue excluding treasury shares. The filing states that the total number of voting rights in the company is 4,067,451,066, and that this figure "may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules." The company confirmed that the percentage of voting rights attributable to treasury shares following the transfer is 6.12%. The filing was signed by Victoria Whyte, Company Secretary, on behalf of GSK plc (NYSE:GSK).
What Was Disclosed
GSK plc disclosed the transfer of 22,000,000 treasury shares to its ADR depositary on 20 November 2026, resulting in 11,000,000 ADRs issued at $47.82 per ADR to the GlaxoSmithKline (US) Trust for employee incentive plan awards, with 248,881,064 shares remaining in treasury.



Please wait processing your request...